Leronlimab is a large molecule that successfully blocks CCR5 through weekly self-injection under the skin. CCR5 is a receptor that is highly expressed in many diseases and its blocking is useful in combating these diseases. Leronlimab has been tested on over 850 patients, some have been on Leronlimab for 5 years and there is no SAE so far. These are facts that are easy to verify, and anyone who disputes this has no idea about this drug.
Why CYDY has not yet been able to meet the FDA's requirement to continue with the BLA is a problem and it affects the stock price. Whether it's NP or someone else's fault, why it takes so long, whether there are other issues, etc., we can debate and speculate, but Leronlimab is real and blocks CCR5 very well without SAE. Period.